The UNC Lineberger Comprehensive Cancer Center requests renewal of its National Cancer Institute (NCI) Center Core Support Grant (CCSG) for Years 25-29. Over the past ten years and especially in the past five years, the UNC Lineberger has grown tremendously and emerged as a national leader in cancer research. Total National Cancer Institute (NCI) awards to Center members have tripled over the past ten years (1988: $7.2 million; 1993: $14.1 million; 1998: $22.6 million). In the past five years, the Center has recruited more than 25 new clinical and translational science members. Accrual to institutional to institutional therapeutic clinical trials at UNC has tripled (1993: 66; 1998: 190), while total accrual to therapeutic trials has almost doubled (1993: 188; 1998: 190), while total accrual to therapeutic trials has almost doubled (1993: 188; 1998: 347) in 1998. The Center has doubled the size of its headquarters building (39,000 to 80,000 nsf). The State budget has doubled and the Cancer Center, the UNC Hospitals, and the UNC School of Medicine entered into an enhanced and funded partnership ($1 million per year) that makes oncology and the Cancer Center a centerpiece of the emerging UNC Health Care System. Administratively, in 1993 the Center had direct responsibility for $15.1 million and had 211 employees on payroll. In 1998, the Center directly administers $32.4 million and has 517 employees on payroll. Under the leadership by Dr. H. Shelton """"""""Shelly"""""""" Earp the UNC Lineberger is well positioned to continued this remarkable growth over the next five years. The Cancer Center seeks significant new NCI Center Core Support Grant (CCSG) funding to match its expanded institutional commitment and continue its tradition of growth and development in collaborative cancer research. The total request of $3.495 million will support 10 scientific programs, 21 shared resources, five staff investigators, developmental funding, leadership, planning and evaluation, and administration. Requested support is approximately double the existing CCSG funding of $1,729 million. 85% of the increase is for seven specific requests, primarily for new and expanded shared resources. These requests are: New Shared Resources for Population Sciences: Expanded Shared Resources for Clinical Research; Expanded Shared Resources for Biostatistics; New Shared Resources for Translational and Basic Science; Expanded shared resources for Biostatistics; New Shared Resources for Translational and Basic Science; Expanded Shared Resources for Animal Models of Cancer; Increased Developmental Funding for Continued Expansion and Enhancement; and Staff Investigators in Key Developing Areas. Over the past 25 years and especially during the past decade, the Center has grown from a small center focused on basic laboratory science to large, truly comprehensive cancer center. With a strong tradition of growth and excellence, increased institutional commitment, and new leadership, and a strategic plan to guide development, the UNC Lineberger eagerly looks forward to continued development of its comprehensive programs over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016086-26S1
Application #
6447752
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1981-08-01
Project End
2004-11-30
Budget Start
2001-04-25
Budget End
2001-11-30
Support Year
26
Fiscal Year
2001
Total Cost
$145,208
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Dronamraju, Raghuvar; Jha, Deepak Kumar; Eser, Umut et al. (2018) Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. Nucleic Acids Res 46:1331-1344
Koehler, Jennifer W; Miller, Andrew D; Miller, C Ryan et al. (2018) A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. J Neuropathol Exp Neurol 77:1039-1054
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059

Showing the most recent 10 out of 1525 publications